Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07313592 · ClinicalTrials.gov registry record
Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
A clinical trial, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- 60
- Enrollment target
NCT07313592: Recruiting study, sponsored by Washington University School of Medicine.
NCT07313592 is a clinical trial that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07313592 is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
This is a prospective specimen collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young adult acute lymphoid leukemia (ALL) patients. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup, and the patients will then be followed for clinical outcomes for up to 65 months.
Primary Outcome
ChromoSeq® will be successful if the results on the first attempt in a real-time, clinical setting identifies recurrent structural variants and copy number alterations of conventional cytogenetics and karyotype. The success rate and the 95% confidence interval will be calculated.
Interventions
- DEVICE ChromoSeq® assay testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2028-07-15 |
What NCT07313592 shows while recruiting
NCT07313592 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ChromoSeq® assay testing is the first listed.
NCT07313592 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07313592 about?
NCT07313592 is a clinical study titled "Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients". This is a prospective specimen collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young adult acute lymphoid leukemia (ALL) patients. Sixty patients will undergo collections of bone marrow and/or perip...
What is the current status of trial NCT07313592?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-06-03. Estimated completion is 2028-07-15.
What interventions are being tested in trial NCT07313592?
The interventions under investigation include: ChromoSeq® assay testing (DEVICE).
Who is sponsoring clinical trial NCT07313592?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI